Nicotine replacement therapy (NRT)

Phase 1

Nicotine replacement therapy (NRT) is one of 46 therapeutic programs targeting Nicotine Dependence. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Nicotine DependenceRecruiting

Tobacco Use CessationNot yet recruiting

Nicotine DependencePhase 1

Recruiting

Tobacco Use CessationPreclinical

Not yet recruiting

Competition

Competitive Landscape

45 competitors in Nicotine Dependence

#DrugCompanyPhaseTrials

Nicorette

Pfizer

Approved

5 2

Ritalin

Novartis

Approved

1 3

Revia

Teva

Approved

1 4

Lopid

Minipress

Niacor

Aricept

Epidiolex

Rozerem

Bayer Aspirin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Nicotine Dependence

NCT07007195

Q4 2027

PreclinicalNot yet recruiting

Tobacco Use Cessation

NCT07694492

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Pilot Study in Cancer Patients Scheduled for Surgery Evaluating Different Smoking Cessation Protocols : Nicotine Replacement (NRT), Motivational Interviewing (MI), Cognitive Behavioural Therapy (CBT) or Hypnotherapy

Terminated·IInstitut Cancerologie de l'Ouest·Preclinical·NCT04899492·21 enrolled

Tobacco Use Cessation1 trial

Determining the Feasibility of Utilizing a Medical-Legal Partnership Model to Reach Coal Miners Who Use Tobacco and Nicotine Products and Connect Them to a Pharmacy-based Cessation Program

Not yet recruiting·UUniversity of Virginia·Preclinical·NCT07694492·120 enrolled

Nicotine Dependence1 trial

An Innovative Digitally-Delivered Olfactory Method for Reducing Cigarette Cravings and Supporting Smoking Cessation

Recruiting·UUniversity of Houston·Phase 1·NCT07007195·132 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Nicotine replacement therapy (NRT). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Nicotine replacement therapy (NRT). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Houston company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: UUniversity of Houston

Nicotine replacement therapy (NRT)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Trials by Indication[1]

Breast Cancer1 trial

Tobacco Use Cessation1 trial

Nicotine Dependence1 trial

References

Drug Info

Quick Facts

Related News